Incyte’s Commitment to Patients

Patient Safety

Patient safety is a top priority at Incyte. We believe that conducting clinical trials for review by global regulatory authorities to obtain the necessary approvals provides patients with the optimal mechanism for broad access to medicines as prescribed by qualified healthcare professionals. As such, we are committed to adhering to the applicable laws and regulations imposed in all territories in which we operate clinical trials and to conducting trials in an ethical manner. In doing so, we help to ensure that there is an appropriate risk-to-benefit ratio before initiating a new clinical trial. We then have protocols in place to obtain informed consent.

Most clinical trials intended to support the efficacy and safety profile of an investigational product proceed to full completion of planned sample size accrual without interim review of data generated during the trial. However, certain drug development plans involve the need to access interim data for a variety of reasons, such as ensuring participant safety. Incyte is committed to the supervision of all ongoing trials through an institutional review board, an ethics committee, and/or a research ethics board in order to protect the safety of trial participants.

As a matter of transparency and ethics, Incyte is committed to announcing applicable trial results, positive or negative, on clinicaltrials.gov or other applicable registries, at appropriate medical meetings, and in peer-reviewed journals in a timely manner. Publication of these data are scientifically responsible and may serve to benefit both patients as well as the entire scientific community as we collectively seek to transform the treatment of cancer and other diseases.

Scientific Excellence

We hold our clinical research to the highest standards of scientific and ethical rigor and we strive to implement programs and initiatives to allow for broad access to our medicines for appropriate patients. We execute on this commitment through our rigorous discovery process, our adherence to clinical trial standards set by the FDA and other global regulatory bodies, and our focus on data transparency from applicable trials through presentations of both positive and negative data at appropriate medical meetings and in peer-reviewed journals.

Our portfolio speaks to our commitment to improving the treatment of cancer and other diseases. We now have 3 discovery platforms: small molecule, monoclonal antibody, and bi-specific antibody platforms. We believe that this multifaceted approach positions us well as we seek to utilize these different treatment modalities to evaluate a diverse spectrum of therapeutic targets.

As the effort to bring transformative treatments to patients with cancer is a significant undertaking, we are committed to partnering with companies, universities, and research institutions in order to share knowledge, resources, and ideas that may best benefit patients.

Incyte may also provide our investigational products and/or financial support for research by third parties related to our products that address therapeutic areas of interest to us. We are committed to ensuring that these investigator-initiated research trials (IIRs) are submitted, reviewed, and, if
approved, conducted and funded in a standardized, consistent and transparent manner. Incyte is also committed to ensuring that our interactions with study investigators comply with all applicable legal and ethical standards and obligations.

**Access to Medicine**

Incyte is committed to the goal of making sure that eligible patients have access to appropriate treatments. We believe that conducting clinical trials for review by global regulatory authorities to obtain the necessary approvals provides patients with an important mechanism for increased access to medicines as prescribed by qualified healthcare professionals.

We are committed to ensuring that eligible patients have access to applicable clinical trials by providing them with information and resources to support their treatment journeys, consistent with applicable laws, regulations and ethical guidelines. Some patients with serious or immediately life threatening diseases or conditions may not be eligible for participation in a clinical trial or may not otherwise have other options. In these cases, we may choose to provide eligible patients with access to an unapproved or investigational product through expanded access. For more information, please click [here](#) for our policy on compassionate use.

Our IncyteCARES (Connecting to Access, Reimbursement, Education and Support) program supports eligible patients in the United States before and during applicable treatment through ongoing education, resources, as well as a dedicated nursing support program. For more information, please click [here](#).

**Patient Education and Awareness**

Incyte is committed to providing patients with the resources they need as they embark on their own patient journey. To learn more about our efforts, please click [here](#).